White House considers rules to overhaul shareholder voting- WSJ
SECAUCUS, N.J. - Quest Diagnostics (NYSE:DGX) announced Tuesday that its Board of Directors has declared a quarterly cash dividend of $0.80 per share, representing a current yield of 1.74% based on the company’s stock price of $188.85. According to InvestingPro data, Quest has maintained dividend payments for 22 consecutive years and has raised its dividend for 14 straight years.
The dividend will be payable on January 28, 2026, to shareholders of record of Quest Diagnostics common stock on January 13, 2026, according to a company press release. The diagnostic services provider has shown a dividend growth rate of 6.67% over the last twelve months.
Quest Diagnostics is a provider of diagnostic information services that serves approximately one-third of adult Americans and half of the physicians and hospitals in the United States annually.
The company employs more than 55,000 people and specializes in laboratory testing services that provide diagnostic insights from clinical lab results.
In other recent news, Quest Diagnostics reported its third-quarter earnings for 2025, surpassing expectations for both earnings per share (EPS) and revenue. The company achieved an adjusted EPS of $2.60, exceeding the forecasted $2.50, and reported revenues of $2.82 billion, which were above the expected $2.73 billion. Quest Diagnostics also raised its fiscal year 2025 guidance, signaling confidence in its future performance. Following these results, Truist Securities increased its price target for Quest Diagnostics from $195 to $205, maintaining a Hold rating on the stock. Similarly, Leerink Partners raised its price target from $203 to $210, maintaining an Outperform rating. Leerink noted a favorable environment in the laboratory services sector, citing stable reimbursement and utilization trends. These developments reflect a positive outlook among analysts for Quest Diagnostics, based on its strong quarterly performance and sector conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.